[1]
|
Garrido-Castro, A.C., Lin, N.U. and Polyak, K. (2019) Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. Cancer Discovery, 9, 176-198.
https://doi.org/10.1158/2159-8290.CD-18-1177
|
[2]
|
Jiang, Y.Z., Ma, D., Suo, C., et al. (2019) Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell, 35, 428-440. https://doi.org/10.1016/j.ccell.2019.02.001
|
[3]
|
Cho, B., Han, Y., Lian, M., et al. (2019) Evaluation of Racial/Ethnic Differences in Treatment and Mortality among Women with Triple-Negative Breast Cancer. JAMA Oncolo-gy, 7, 1016-1023.
|
[4]
|
Poggio, F., Bruzzone, M., Ceppi, M., et al. (2018) Platinum-Based Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer: A Systematic Review and Meta-Analysis. Annals of Oncology, 29, 1497-1508.
https://doi.org/10.1093/annonc/mdy127
|
[5]
|
Lyons, T.G. (2019) Targeted Therapies for Triple-Negative Breast Cancer. Current Treatment Options in Oncology, 20, Article No. 82. https://doi.org/10.1007/s11864-019-0682-x
|
[6]
|
Wu, S.Y., Xu, Y., Chen, L., et al. (2022) Combined Angiogenesis and PD-1 Inhibition for Immunomodulatory TNBC: Concept Exploration and Biomarker Analysis in the FUTURE-C-Plus Trial. Molecular Cancer, 21, Article No. 84.
https://doi.org/10.1186/s12943-022-01536-6
|
[7]
|
Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674.
https://doi.org/10.1016/j.cell.2011.02.013
|
[8]
|
Hainaut, P. and Plymoth, A. (2013) Targeting the Hallmarks of Cancer: Towards a Rational Approach to Next- Generation Cancer Therapy. Current Opinion in Oncology, 25, 50-51.
https://doi.org/10.1097/CCO.0b013e32835b651e
|
[9]
|
Sui, S., Xu, S. and Pang, D. (2022) Emerging Role of Fer-roptosis in Breast Cancer: New Dawn for Overcoming Tumor Progression. Pharmacology & Therapeutics, 232, Article ID: 107992.
https://doi.org/10.1016/j.pharmthera.2021.107992
|
[10]
|
Song, C.W., Clement, J.J. and Levitt, S.H. (1976) Preferen-tial Cytotoxicity of 5-Thio-D-glucose against Hypoxic Tumor Cells. JNCI: Journal of the National Cancer Institute, 57, 603-605. https://doi.org/10.1093/jnci/57.3.603
|
[11]
|
Badgley, M.A., Kremer, D.M., Maurer, H.C., et al. (2020) Cysteine Depletion Induces Pancreatic Tumor Ferroptosis in Mice. Science, 368, 85-89. https://doi.org/10.1126/science.aaw9872
|
[12]
|
Xu, T., Ding, W., Ji, X., et al. (2019) Molecular Mechanisms of Ferroptosis and Its Role in Cancer Therapy. Journal of Cellular and Molecular Medicine, 23, 4900-4912. https://doi.org/10.1111/jcmm.14511
|
[13]
|
Schonberg, D.L., Miller, T.E., Wu, Q., et al. (2015) Preferential Iron Trafficking Characterizes Glioblastoma Stem- Like Cells. Cancer Cell, 28, 441-455. https://doi.org/10.1016/j.ccell.2015.09.002
|
[14]
|
Chen, M.S., Wang, S.F., Hsu, C.Y., et al. (2017) CHAC1 Degra-dation of Glutathione Enhances Cystine-Starvation- Induced Necroptosis and Ferroptosis in Human Triple Negative Breast Cancer Cells via the GCN2-eIF2α-ATF4 Pathway. Oncotarget, 8, 114588-114602. https://doi.org/10.18632/oncotarget.23055
|
[15]
|
Yang, W.S., SriRamaratnam, R., Welsch, M.E., et al. (2014) Regu-lation of Ferroptotic Cancer Cell Death by GPX4. Cell, 156, 317-331. https://doi.org/10.1016/j.cell.2013.12.010
|
[16]
|
Bansal, A. and Simon, M.C. (2018) Glutathione Metabolism in Cancer Progression and Treatment Resistance. Journal of Cell Biology, 217, 2291-2298. https://doi.org/10.1083/jcb.201804161
|
[17]
|
Tang, X., Ding, C.K., Wu, J., et al. (2017) Cystine Addiction of Tri-ple-Negative Breast Cancer Associated with EMT Augmented Death Signaling. Oncogene, 36, 4235-4242. https://doi.org/10.1038/onc.2016.394
|
[18]
|
Rodenhiser, D.I. andrews, J., Kennette, W., et al. (2008) Epigenetic Mapping and Functional Analysis in a Breast Cancer Metastasis Model Using Whole-Genome Promoter Tiling Microar-rays. Breast Cancer Research, 10, R62.
https://doi.org/10.1186/bcr2121
|
[19]
|
Komatsu, S., Moriya, S., Che, X.F., et al. (2013) Combined Treatment with SAHA, Bortezomib, and Clarithromycin for Concomitant Targeting of Aggresome Formation and Intracellular Proteolyt-ic Pathways Enhances ER Stress- Mediated Cell Death in Breast Cancer Cells. Biochemical and Biophysical Research Communications, 437, 41-47.
https://doi.org/10.1016/j.bbrc.2013.06.032
|
[20]
|
Namdar, M., Perez, G., Ngo, L., et al. (2010) Selective Inhibition of Histone Deacetylase 6 (HDAC6) Induces DNA Damage and Sensitizes Transformed Cells to Anticancer Agents. Proceedings of the National Academy of Sciences of the United States of America, 107, 20003-20008. https://doi.org/10.1073/pnas.1013754107
|
[21]
|
Li, T., Zhang, C., Hassan, S., et al. (2018) Histone Deacetylase 6 in Cancer. Journal of Hematology & Oncology, 11, Article No. 111. https://doi.org/10.1186/s13045-018-0654-9
|
[22]
|
Feinberg, A.P. (2007) Phenotypic Plasticity and the Epigenetics of Human Disease. Nature, 447, 433-440.
https://doi.org/10.1038/nature05919
|
[23]
|
Elsheikh, S.E., Green, A.R., Rakha, E.A., et al. (2009) Global Histone Modifications in Breast Cancer Correlate with Tumor Phenotypes, Prognostic Factors, and Patient Outcome. Cancer Re-search, 69, 3802-3809.
https://doi.org/10.1158/0008-5472.CAN-08-3907
|
[24]
|
Lee, S.W., Yeon, S.K., Kim, G.W., et al. (2021) HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma. International Journal of Molecular Sciences, 22, Article 1341.
https://doi.org/10.3390/ijms22031341
|
[25]
|
Yu, S., Cai, X., Wu, C., et al. (2017) Targeting HSP90-HDAC6 Regu-lating Network Implicates Precision Treatment of Breast Cancer. International Journal of Biological Sciences, 13, 505-517. https://doi.org/10.7150/ijbs.18834
|
[26]
|
Marcus, A.I., Zhou, J., O’Brate, A., et al. (2005) The Synergistic Combination of the Farnesyl Transferase Inhibitor Lonafarnib and Paclitaxel Enhances Tubulin Acetylation and Requires a Functional Tubulin Deacetylase. Cancer Research, 65, 3883-3893. https://doi.org/10.1158/0008-5472.CAN-04-3757
|
[27]
|
Aldana-Masangkay, G.I., Rodriguez-Gonzalez, A., Lin, T., et al. (2011) Tubacin Suppresses Proliferation and Induces Apoptosis of Acute Lymphoblastic Leukemia Cells. Leukemia & Lymphoma, 52, 1544-1555.
https://doi.org/10.3109/10428194.2011.570821
|
[28]
|
Zuo, Q., Wu, W., Li, X., et al. (2012) HDAC6 and SIRT2 Promote Bladder Cancer Cell Migration and Invasion by Targeting Cortactin. Oncology Reports, 27, 819-824.
|
[29]
|
Kim, C., Gao, R., Sei, E., et al. (2018) Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. Cell, 173, 879-893.e13. https://doi.org/10.1016/j.cell.2018.03.041
|
[30]
|
Romayor, I., García-Vaquero, M.L., Márquez, J., et al. (2022) Discoidin Domain Receptor 2 Expression as Worse Prognostic Marker in Invasive Breast Cancer. The Breast Journal, 2022, Article ID: 5169405.
https://doi.org/10.1155/2022/5169405
|
[31]
|
Wu, C., Ying, J., Dai, M., Peng, J., et al. (2022) Co-Expression of DDR2 and IFITM1 Promotes Breast Cancer Cell Proliferation, Migration and Invasion and Inhibits Apoptosis. Journal of Cancer Research and Clinical Oncology, 148, 3385-3398. https://doi.org/10.1007/s00432-022-04110-1
|
[32]
|
Brown, R., Curry, E., Magnani, L., et al. (2014) Poised Epige-netic States and Acquired Drug Resistance in Cancer. Nature Reviews Cancer, 14, 747-753. https://doi.org/10.1038/nrc3819
|
[33]
|
Dworkin, A.M., Huang, T.H. and Toland, A.E. (2009) Epigenetic Alterations in the Breast: Implications for Breast Cancer Detection, Prognosis and Treatment. Seminars in Cancer Biology, 19, 165-171.
https://doi.org/10.1016/j.semcancer.2009.02.007
|
[34]
|
Zhao, Y., Li, Y., Zhang, R., et al. (2020) The Role of Erastin in Ferroptosis and Its Prospects in Cancer Therapy. OncoTargets and Therapy, 13, 5429-5441. https://doi.org/10.2147/OTT.S254995
|
[35]
|
Hao, H., Cao, L., Jiang, C., et al. (2017) Farnesoid X Receptor Regula-tion of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis. Cell Metabolism, 25, 856-867.e5. https://doi.org/10.1016/j.cmet.2017.03.007
|
[36]
|
Zheng, D., Liu, J., Piao, H., et al. (2022) ROS-Triggered Endothe-lial Cell Death Mechanisms: Focus on Pyroptosis, Parthanatos, and Ferroptosis. Frontiers in Immunology, 13, Article ID: 1039241.
https://doi.org/10.3389/fimmu.2022.1039241
|